Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
On March 11, 2018, Charles Li, Ph.D. was appointed to the Board. Dr. Li will serve as a director of the Company until the next annual meeting of stockholders of the Company and until his successor is elected and qualified. Dr. Li has also been appointed as a member of the Audit Committee of the Board.
Dr.Li has been a senior analyst at Puissance Capital Management since 2015 and has been involved in many of Puissance Capital’s investments. Prior to joining Puissance Capital, Dr. Li worked at Fosun Capital and Harvest Fund. Dr. Li received his Ph.D. in Applied Physics from Harvard University, and a B.S. and B.A. from Xi’an Jiaotong University in Xi’an, China.
Dr. Li will participate in the Company’s standard non-employee director compensation program. to this program, as a non-employee director, Dr. Li is eligible to receive (a) an annual retainer of $35,000 for his service on the Board and an additional fee of $7,500 per year for his services as a member of the Audit Committee, and (b) an annual grant of 25,000 options which become exercisable in 12 equal monthly installments over a one-year period.
It also is anticipated that Dr. Li will enter into the Company’s standard form indemnification agreement for directors of the Company.
On March 12, 2018, the Company issued a press release announcing the departure of Messrs. Looby and Palefsky and Ms. Wendell, the appointment of Mr. Peurach as the Company’s new President and Chief Executive Officer and the election of Dr. Li to the Board. A copy of this press release is filed as Exhibit 99.2 to this current report.
| Item 9.01 | Financial Statements and Exhibits |
EKSO BIONICS HOLDINGS, INC. ExhibitEX-99.1 2 tv488317_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 SEPARATION AGREEMENT AND FULL RELEASE OF ALL CLAIMS Whereas,…To view the full exhibit click here
